H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on VRDN stock, giving a Buy rating today.Pick the best stocks and maxi ...

Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

A high-level overview of Viridian Therapeutics, Inc. (VRDN) stock. View (VRDN) real-time stock price, chart, news, analysis, analyst reviews and more.

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

The Viridian Capital Chart of the Week highlights key investment, ... Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10.

WALTHAM, Mass., May 30, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for ...